IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Tomasoni, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.860
NA - Nord America 2.662
EU - Europa 1.494
SA - Sud America 856
AF - Africa 70
OC - Oceania 5
Totale 7.947
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.563
SG - Singapore 1.131
BR - Brasile 742
CN - Cina 588
HK - Hong Kong 529
IT - Italia 360
DE - Germania 302
VN - Vietnam 204
FI - Finlandia 162
RU - Federazione Russa 157
TR - Turchia 132
GB - Regno Unito 126
IE - Irlanda 69
IN - India 69
UA - Ucraina 59
AR - Argentina 51
BD - Bangladesh 49
CA - Canada 43
FR - Francia 39
MX - Messico 36
CZ - Repubblica Ceca 35
NL - Olanda 32
JP - Giappone 30
PL - Polonia 30
ZA - Sudafrica 29
IQ - Iraq 28
SE - Svezia 27
AT - Austria 25
ES - Italia 22
EC - Ecuador 17
PK - Pakistan 17
SA - Arabia Saudita 16
MA - Marocco 12
CO - Colombia 11
ID - Indonesia 11
VE - Venezuela 11
KE - Kenya 10
EG - Egitto 9
PE - Perù 9
AE - Emirati Arabi Uniti 8
BE - Belgio 8
TN - Tunisia 7
BG - Bulgaria 6
LT - Lituania 6
PH - Filippine 6
UZ - Uzbekistan 6
LV - Lettonia 5
NP - Nepal 5
PY - Paraguay 5
TT - Trinidad e Tobago 5
CH - Svizzera 4
PA - Panama 4
AZ - Azerbaigian 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
UY - Uruguay 3
AU - Australia 2
CL - Cile 2
GY - Guiana 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
MK - Macedonia 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
SN - Senegal 1
SV - El Salvador 1
TM - Turkmenistan 1
Totale 7.947
Salva come PNG Salva come JPEG
Città #
Hong Kong 527
Singapore 491
Ashburn 337
Beijing 243
Los Angeles 141
Chandler 138
New York 136
Helsinki 116
Istanbul 113
Munich 106
Fairfield 102
Dallas 95
The Dalles 85
Ho Chi Minh City 78
Princeton 75
Dublin 69
São Paulo 67
Redondo Beach 61
Moscow 58
Buffalo 57
Frankfurt am Main 57
Romola 55
Milan 52
Chicago 51
Houston 45
San Francisco 43
Shanghai 40
Woodbridge 40
Hanoi 36
Wilmington 35
Seattle 34
Cambridge 32
Brescia 27
Jacksonville 27
Brno 26
Tokyo 26
Brooklyn 24
Turku 24
Boston 23
Ann Arbor 22
London 22
Montreal 22
Warsaw 22
Santa Clara 21
Atlanta 18
Lappeenranta 18
Nuremberg 18
Belo Horizonte 17
Düsseldorf 16
Haiphong 15
Orem 15
Poplar 15
Stockholm 15
Washington 15
Brasília 14
Rio de Janeiro 14
Rome 14
Denver 13
Guangzhou 13
Johannesburg 12
Kilburn 12
Phoenix 12
Porto Alegre 12
Toronto 12
Chennai 11
Curitiba 11
Salvador 11
Vienna 11
Baghdad 10
Buenos Aires 10
Charlotte 10
City of London 10
Amsterdam 9
Campinas 9
Dhaka 9
Erbil 9
Mumbai 9
Trieste 9
Ankara 8
Biên Hòa 8
Brussels 8
Changsha 8
Kyiv 8
Manchester 8
Nairobi 8
Newark 8
Querétaro 8
Salt Lake City 8
Cape Town 7
Da Nang 7
Guayaquil 7
Maringá 7
Mexico City 7
Pune 7
Thái Bình 7
Caxias do Sul 6
Fortaleza 6
Hortolândia 6
Jeddah 6
Juiz de Fora 6
Totale 4.488
Salva come PNG Salva come JPEG
Nome #
August 2020 at a glance: focus on neurohormonal antagonists and electrolytes 135
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 134
Acute heart failure: More questions than answers 112
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study 112
Clinical characteristics and outcome of acute heart failure patients with mid-range ejection fraction. 104
Review: Evidence-Based Management of Acute Heart Failure 98
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 97
COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease 94
In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department 94
Highlights in heart failure 92
Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score 85
The prognostic value of serial troponin measurements in patients admitted for COVID-19 85
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 84
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure 84
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 84
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 83
2024 update in heart failure 81
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 80
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 80
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 79
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 79
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 73
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 73
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 73
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 73
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 72
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 72
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 72
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 71
Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming 71
COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae 70
[Transcatheter devices for chronic heart failure: state of the art] 70
Prognostic significance of serum potassium in patients hospitalized for acute heart failure 69
[Empagliflozin and heart failure: the EMPEROR-Reduced trial] 69
September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy 69
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 67
[Sodium-glucose cotransporter 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies] 67
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation 67
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 66
Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. 66
July 2020 at a glance: focus on imaging and cardiomyopathies 66
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 65
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 64
Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration 64
A year in heart failure: an update of recent findings 64
April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction 63
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction 63
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices 63
Heart failure in the last year: progress and perspective 63
Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC 61
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines 60
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 60
Heart failure: an update from the last years and a look at the near future 60
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 60
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists 59
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice 58
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial 57
Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure 57
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 56
Coronavirus disease 2019 and cardiovascular disease: what we have learnt during the last 2 years 56
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC 55
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 54
August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis 54
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis 54
April 2023 at a glance: focus on diagnosis and comorbidities 53
Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation 53
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 53
Impact of malnutrition in patients with severe heart failure 52
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 52
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 51
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 51
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 50
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 50
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction 49
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials 49
Coronary artery disease: novel insights in a long-standing disease 49
Impact of Pulmonary Hypertension on Outcomes after Transcatheter Tricuspid Valve Edge-to-Edge Repair 49
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 49
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 49
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis 49
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 47
March 2023 at a glance: pathophysiology, medical therapy and devices 47
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial 47
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 47
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction 47
Addressing comorbidities in heart failure: When feeling better and living longer go in the same direction 46
January 2023 at a glance: focus on acute heart failure and medical therapy 46
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 46
Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy 46
December 2020 at a glance: focus on COVID-19, comorbidities and palliative care 45
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 45
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial 45
NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial 44
January 2022 at a glance: time for the new ESC guidelines on heart failure 43
October 2022 at a glance: focus on clinical trials 43
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices 43
Tailored therapies for patients affected by systemic sclerosis with primary heart involvement: The role of rituximab 43
Management of hypertrophic cardiomyopathy 43
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis 43
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial 43
Totale 6.449
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021271 0 0 0 0 0 20 89 68 20 38 21 15
2021/2022202 4 41 4 6 8 6 8 10 14 10 18 73
2022/2023486 59 36 8 18 36 137 7 32 73 15 31 34
2023/20241.152 59 13 106 90 74 136 82 23 278 38 43 210
2024/20252.595 21 28 95 247 247 229 283 124 212 271 486 352
2025/20263.252 567 767 480 871 502 65 0 0 0 0 0 0
Totale 8.064